Expand GLUE Menu
GLUE MENU

GLUE Latest Press Releases

-- December 16, 2025 --

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations Globe Newswire 7:00 AM

-- December 15, 2025 --

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results Globe Newswire 4:01 PM

-- November 8, 2025 --

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases Globe Newswire 11:30 AM

-- November 6, 2025 --

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates Globe Newswire 7:00 AM

-- November 3, 2025 --

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- October 24, 2025 --

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases Globe Newswire 7:00 AM

-- September 15, 2025 --

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases Globe Newswire 7:00 AM

-- September 2, 2025 --

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 7, 2025 --

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes